Determining Cross-Contamination Risks in Multiproduct Biopharmaceutical Facilities

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-05-15-2014, Volume 2014 eBook, Issue 2

A global contract manufacturer of biologics discusses the increasing impact of health-based exposure limits in assessing cross-contamination risks.

 

A global contract manufacturer of biologics discusses the increasing impact of health-based exposure limits in assessing cross-contamination risks.

Advertisement

Download

.

 

 

 

 

 

 

 

Related Content:

Biologic DrugsDosage FormsPharmaceutical Technology-05-15-2014
Behind the Headlines: Sickle Cell Therapies; Mpox Vaccines; and ARCH Ventures’ Biotech Fund
Adare, Laxxon to Collaborate on 3D-Printed Oral Dosage Forms
Responding to Mpox